Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The treatment method was found to be safe and effective in comparison with surgery or radiation.
New research discusses how immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.
Metastatic kidney cancer patients with greater microbial diversity had better outcomes with immunotherapy.
The targeted therapy shrank tumors in more than half of people with previously treated non-small-cell lung cancer.
Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.
Researchers reported significant changes in liver, cardiovascular and diabetes markers.
Stivarga also improved survival in those with recurrent HCC after a liver transplant.
Premenopausal women with breast cancer who had been treated with radiation for a childhood cancer had worse breast cancer-specific survival.
People who switched showed improvement in markers of kidney and bone health but also rise in lipid levels.
Liver complications, heart disease and non-liver cancers also account for most deaths among people with hepatitis B or C.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
The reduction in mortality was most evident during the first 10 years of follow-up after the first scan at age 40.
Homeless people, incarcerated individuals and people with mental health conditions achieved a high cure rate.
Scientists discover a single gene’s role in drug resistance and look for ways to re-sensitize tumors to chemotherapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.